Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 18INDUSTRY 4FED 2NIH 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 410Lymphoma 304Carcinoma, Non-Small-Cell Lung 262Melanoma 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 251Prostatic Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 242Leukemia, Myeloid, Acute 222Lung Neoplasms 215Neoplasms 209Colonic Neoplasms 209Lymphoma, Non-Hodgkin 207Lymphoma, Large B-Cell, Diffuse 204Leukemia 200Multiple Myeloma 197Lymphoma, Follicular 197Colorectal Neoplasms 190Rectal Neoplasms 188Ovarian Neoplasms 184Burkitt Lymphoma 179Brain Neoplasms 171Neoplasm Metastasis 166Lymphoma, Mantle-Cell 163Carcinoma, Renal Cell 163Glioblastoma 161Sarcoma 156Pancreatic Neoplasms 146Lymphoma, B-Cell, Marginal Zone 143Unspecified Adult Solid Tumor, Protocol Specific 138Gliosarcoma 133

Interventions

Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Interventional × Arthritis × Clear all
NCT00017680 2008-06-09

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Office of Rare Diseases (ORD)

Phase 2 Completed
25 enrolled
Other hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Arthritis, Connective Tissue Diseases, Hematologic Neoplasms, Genetic Diseases, Inborn, Rare Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡